But you also outlined a series of drugs that will require a substantial amount of capital on your side. We were supported in this most recent round by Canaan Partners, a major U.S. venture capital company. Our existing investors, led by Nomura International Plc and 3I Group Plc, also participated in this round. In that time frame, we will allocate approximately 80 percent of the proceeds to clinical development and 20 percent to commercial. Oral naltrexone tablets will establish the company in the commercial market and sow the seeds for our introduction of Naltrexone Depot to treat alcohol and opiate addicts, hopefully, in 2003.
Home runs are always extremely difficult.
If you talk to a pharmaceutical executive, I believe that our 2.5 percent market share, would be viewed as extremely disappointing. We will probably launch in the United States followed by Europe because there are slightly different definitions of the patient populations in Europe, and they vary in every country. We are conducting the clinical trials which we believe are necessary to facilitate the registration of our portfolios. I hope that our close working relationships will enable us to get these products approved in a timely manner. Our core strength is clinical development and, in the future, sales and marketing.